<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213706</url>
  </required_header>
  <id_info>
    <org_study_id>20090748</org_study_id>
    <nct_id>NCT01213706</nct_id>
  </id_info>
  <brief_title>Effect of Whole Body Periodic Acceleration on Airway Endothelial Function</brief_title>
  <official_title>Effect of Whole Body Periodic Acceleration on Airway Endothelial Function in Healthy Smokers, Non-smokers and Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present proposal the investigators wish to assess the effect of a single session with
      the device known as Exer-Rest速 which applies Whole Body Periodic Acceleration (WBPA) on
      baseline airway blood flow (Qaw) and in Qaw variation, in current smokers,
      glucocorticoid-na誰ve asthmatics, and age-matched healthy never-smokers, with the expectation
      that the treatment will transiently increase the Qaw, and to a greater extent in the current
      smokers and patients with asthma who have endothelial dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial shear stress activates nitric oxide synthase (NOS), leading to
      endothelium-dependent vasodilation. This can be accomplished through exercise or with a
      device known as Exer-Rest速 which applies Whole Body Periodic Acceleration (WBPA) that is also
      called pGz. WBPA produces systemic vasodilation, by exerting shear stress on the vascular
      endothelium, activating endothelial NOS and releasing NO in animal models and human subjects.
      Cigarette smoking is associated with attenuated vascular relaxation responses in the systemic
      circulation. Patients with asthma also exhibit endothelial dysfunction in the airway. In this
      study the investigators wish to assess the effect of a single pGz session on baseline Qaw and
      delta Qaw in current smokers, glucocorticoid-na誰ve asthmatics, and age-matched healthy
      never-smokers to test if this treatment will increase the vascular relaxation responses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway Blood Flow Response to Albuterol</measure>
    <time_frame>Qaw post minus Qaw pre albuterol after WBPA or Sham WBPA</time_frame>
    <description>Airway Blood Flow will be measured before and 15 minutes after the 180 mcg of albuterol inhalation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <condition>Smokers</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Whole Body Periodic Acceleration (WBPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham WBPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham WBPA :
All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Whole Body Periodic Acceleration (WBPA)</intervention_name>
    <description>Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.</description>
    <arm_group_label>Whole Body Periodic Acceleration (WBPA)</arm_group_label>
    <arm_group_label>Sham WBPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham WBPA</intervention_name>
    <description>The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.</description>
    <arm_group_label>Whole Body Periodic Acceleration (WBPA)</arm_group_label>
    <arm_group_label>Sham WBPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        15 healthy never-smokers, 15 smokers (&gt; than 1 year smoke history) and 15 never-smokers
        asthmatics; FEV1 &gt; 80% (except for asthmatics subjets)

        Exclusion Criteria:

        Women of childbearing potential who do not accepted birth control measures; pregnant and
        breast feeding; cardiovascular disease or use of cardiovascular drugs; respiratory
        infection during the 4 weeks preceding the study; use of inhaled or systemic
        glucocorticoids, leukotriene modifiers or theophyllines in asthmatics; FEV1 &lt; 80% on the
        screening day (excepted for asthmatics subjets)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Wanner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Human Research Laboratory, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sackner MA, Gummels E, Adams JA. Nitric oxide is released into circulation with whole-body, periodic acceleration. Chest. 2005 Jan;127(1):30-9.</citation>
    <PMID>15653959</PMID>
  </reference>
  <reference>
    <citation>Sackner MA, Gummels E, Adams JA. Effect of moderate-intensity exercise, whole-body periodic acceleration, and passive cycling on nitric oxide release into circulation. Chest. 2005 Oct;128(4):2794-803.</citation>
    <PMID>16236957</PMID>
  </reference>
  <reference>
    <citation>Matsumoto T, Fujita M, Tarutani Y, Yamane T, Takashima H, Nakae I, Horie M. Whole-body periodic acceleration enhances brachial endothelial function. Circ J. 2008 Jan;72(1):139-43.</citation>
    <PMID>18159115</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Wanner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>airway blood flow</keyword>
  <keyword>albuterol</keyword>
  <keyword>Whole Body Periodic Acceleration (WBPA)</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Endothelial Dysfunction</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SHAM WBPA Then WBPA</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Sham WBPA</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Hour)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>WBPA</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Whole Body Periodic Acceleration (WBPA)</title>
          <description>Whole Body Periodic Acceleration (WBPA) in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g. These settings have been shown to release NO into the circulation.
Whole Body Periodic Acceleration (WBPA): Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Airway Blood Flow Response to Albuterol</title>
        <description>Airway Blood Flow will be measured before and 15 minutes after the 180 mcg of albuterol inhalation.</description>
        <time_frame>Qaw post minus Qaw pre albuterol after WBPA or Sham WBPA</time_frame>
        <population>controls n =15, smokers N=15 , asthma N=15</population>
        <group_list>
          <group group_id="O1">
            <title>WBPA</title>
            <description>Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.</description>
          </group>
          <group group_id="O2">
            <title>Sham WBPA</title>
            <description>Subjects will be resting on the platform without any WBPA.</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Blood Flow Response to Albuterol</title>
          <description>Airway Blood Flow will be measured before and 15 minutes after the 180 mcg of albuterol inhalation.</description>
          <population>controls n =15, smokers N=15 , asthma N=15</population>
          <units>亮l/min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Smokers n=15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="2.33"/>
                    <measurement group_id="O2" value="-1.43" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls N=15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.93" spread="2.08"/>
                    <measurement group_id="O2" value="4.03" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma N=15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="2.06"/>
                    <measurement group_id="O2" value="1.65" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Whole Body Periodic Acceleration (WBPA)</title>
          <description>Whole Body Periodic Acceleration (WBPA) in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g. These settings have been shown to release NO into the circulation.
Whole Body Periodic Acceleration (WBPA): Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.</description>
        </group>
        <group group_id="E2">
          <title>Sham WBPA</title>
          <description>The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
Sham WBPA: The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Wanner, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305) 243-2568</phone>
      <email>awanner@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

